JP2021517129A5 - - Google Patents
Info
- Publication number
- JP2021517129A5 JP2021517129A5 JP2020546926A JP2020546926A JP2021517129A5 JP 2021517129 A5 JP2021517129 A5 JP 2021517129A5 JP 2020546926 A JP2020546926 A JP 2020546926A JP 2020546926 A JP2020546926 A JP 2020546926A JP 2021517129 A5 JP2021517129 A5 JP 2021517129A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- pharmaceutical composition
- composition according
- cancer
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639587P | 2018-03-07 | 2018-03-07 | |
| US62/639,587 | 2018-03-07 | ||
| US201962807912P | 2019-02-20 | 2019-02-20 | |
| US62/807,912 | 2019-02-20 | ||
| PCT/IB2019/051733 WO2019171253A1 (en) | 2018-03-07 | 2019-03-04 | Anti-pd-1 antibody compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021517129A JP2021517129A (ja) | 2021-07-15 |
| JP2021517129A5 true JP2021517129A5 (enExample) | 2022-03-11 |
| JP7312188B2 JP7312188B2 (ja) | 2023-07-20 |
Family
ID=66041593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546926A Active JP7312188B2 (ja) | 2018-03-07 | 2019-03-04 | 抗ｐｄ－１抗体組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210002369A1 (enExample) |
| EP (1) | EP3761954A1 (enExample) |
| JP (1) | JP7312188B2 (enExample) |
| KR (1) | KR102594028B1 (enExample) |
| CN (1) | CN112105343B (enExample) |
| AU (1) | AU2019232625B2 (enExample) |
| BR (1) | BR112020017935A2 (enExample) |
| IL (1) | IL277095B2 (enExample) |
| MX (1) | MX2020009275A (enExample) |
| WO (1) | WO2019171253A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| US20230035617A1 (en) * | 2019-11-13 | 2023-02-02 | Pfizer Inc. | Stable aqueous anti-tfpi antibody formulation |
| US20230054413A1 (en) * | 2019-12-13 | 2023-02-23 | Samsung Bioepis Co., Ltd. | Stable anti-pd1 antibody pharmaceutical formulations |
| SI4076385T1 (sl) | 2019-12-20 | 2026-04-30 | Formycon Ag | Formulacije protiteles anti-pd1 |
| JP2023512286A (ja) * | 2020-01-31 | 2023-03-24 | サノフイ | 抗体の肺送達 |
| CR20220596A (es) | 2020-05-26 | 2023-01-23 | Boehringer Ingelheim Int | Anticuerpos anti-pd-1 |
| CN113967195A (zh) * | 2020-07-22 | 2022-01-25 | 三生国健药业（上海）股份有限公司 | 抗her2/pd1双特异性抗体冻干制剂及其制备方法 |
| JP2024527517A (ja) * | 2021-06-23 | 2024-07-25 | フォーマイコン アーゲー | 抗ｐｄ１抗体製剤 |
| WO2023274275A1 (zh) * | 2021-07-01 | 2023-01-05 | 天津立博美华基因科技有限责任公司 | 药物组合及其用途 |
| CA3224640A1 (en) * | 2021-07-09 | 2023-01-12 | Krishnan SAMPATHKUMAR | Pharmaceutical compositions of a pd-1 antibody and use of the same |
| CN118076380A (zh) * | 2021-09-03 | 2024-05-24 | 雷迪博士实验室有限公司 | 免疫检查点抑制剂的药物配制物 |
| WO2023031969A1 (en) * | 2021-09-03 | 2023-03-09 | Dr. Reddy’S Laboratories Limited | A method of improving stability of immune check point inhibitors |
| IL314840A (en) * | 2022-03-07 | 2024-10-01 | Mabxience Res S L | Stable Antibody Formulations |
| EP4637818A1 (en) | 2022-12-21 | 2025-10-29 | Formycon AG | Formulations of anti-pd1 antibodies |
| WO2024171082A1 (en) | 2023-02-16 | 2024-08-22 | Sun Pharmaceutical Industries Limited | Stable protein compositions of anti-pd1 antibody |
| TW202508641A (zh) * | 2023-08-16 | 2025-03-01 | 大陸商上海邁晉生物醫藥科技有限公司 | 一種包含免疫綴合物的醫藥組成物及其用途 |
| WO2025174319A1 (en) * | 2024-02-16 | 2025-08-21 | Xbrane Biopharma Ab | Stable antibody formulation for intravenous use comprising nivolumab, histidine, sucrose, polysorbate and methionine |
| SE548163C2 (en) * | 2024-02-16 | 2026-04-13 | Xbrane Biopharma Ab | Stable antibody formulation comprising nivolumab, histidine, sucrose, polysorbate and methionine |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| ES2569409T3 (es) * | 2005-03-08 | 2016-05-10 | Pfizer Products Inc. | Composiciones de anticuerpo anti-CTLA-4 |
| MX2007011767A (es) * | 2005-03-23 | 2007-10-18 | Pfizer Prod Inc | Terapia de combinacion de anticuerpo anti-ctla4 e indolinona para el tratamiento del cancer. |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| PH12012502193A1 (en) * | 2010-05-06 | 2021-08-09 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies |
| EA201391489A1 (ru) * | 2011-04-07 | 2014-02-28 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Композиции со сниженной вязкостью |
| MY175472A (en) * | 2013-09-27 | 2020-06-29 | Genentech Inc | Anti-pdl1 antibody formulations |
| AR099812A1 (es) * | 2014-03-21 | 2016-08-17 | Abbvie Inc | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr |
| TW201617368A (zh) * | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗ｍｆｉ２抗體及使用方法 |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| MX2017009759A (es) * | 2015-01-28 | 2017-10-27 | Pfizer | Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable. |
| CN106999591B (zh) * | 2015-09-28 | 2021-02-23 | 苏州盛迪亚生物医药有限公司 | 一种抗pd-1抗体制剂及其在医药上的应用 |
| WO2017055966A1 (en) * | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
| KR102770786B1 (ko) * | 2017-05-02 | 2025-02-20 | 머크 샤프 앤드 돔 엘엘씨 | 항-tigit 항체 단독의, 및 프로그램화된 사멸 수용체 1 (pd-1) 항체와 조합된 항-tigit 항체의 안정한 제제 및 그의 사용 방법 |
| US10646569B2 (en) * | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
-
2019
- 2019-03-03 IL IL277095A patent/IL277095B2/en unknown
- 2019-03-04 AU AU2019232625A patent/AU2019232625B2/en active Active
- 2019-03-04 BR BR112020017935-3A patent/BR112020017935A2/pt unknown
- 2019-03-04 EP EP19715555.9A patent/EP3761954A1/en active Pending
- 2019-03-04 US US16/978,354 patent/US20210002369A1/en active Pending
- 2019-03-04 KR KR1020207028149A patent/KR102594028B1/ko active Active
- 2019-03-04 JP JP2020546926A patent/JP7312188B2/ja active Active
- 2019-03-04 CN CN201980030480.7A patent/CN112105343B/zh active Active
- 2019-03-04 MX MX2020009275A patent/MX2020009275A/es unknown
- 2019-03-04 WO PCT/IB2019/051733 patent/WO2019171253A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021517129A5 (enExample) | ||
| JP7842070B2 (ja) | 抗ｃｄ３８抗体の皮下製剤及びその使用 | |
| JP2024102215A5 (enExample) | ||
| JP2020518600A5 (enExample) | ||
| JP2021524256A5 (enExample) | ||
| RS56210B1 (sr) | Formulacije sa visokom koncentracijom antitela | |
| JP2018503365A5 (enExample) | ||
| JP2015500207A5 (enExample) | ||
| US8992915B2 (en) | Combination of CD37 antibodies with ICE | |
| RU2017111228A (ru) | Композиции антитела против IL-7R | |
| RU2017107559A (ru) | Лечение раковых заболеваний с применением анти-nkg2a средств | |
| JP7448552B2 (ja) | がんの併用療法 | |
| CA3173919A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer | |
| KR20250004789A (ko) | Pd-1 항체를 함유하는 안정한 고농도 아르기닌 제제 및 그의 사용 방법 | |
| TW202034925A (zh) | Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途 | |
| CN119584995A (zh) | 组合疗法 | |
| RU2020129226A (ru) | Композиции анти-pd-1 антител | |
| EP4722240A1 (en) | Combination of antibodies, or antigen-binding fragments thereof, for the treatment of cancers and compositions thereof | |
| WO2025244529A1 (en) | Dosing regimen of an egfr binding and/or complement activating antibody | |
| TW202612730A (zh) | Ｅｇｆｒ結合和／或補體活化抗體的給藥方案 | |
| HK40126447A (zh) | 抗cd38抗体的皮下制剂及其用途 | |
| AU2024352029A1 (en) | Methods of reducing weight loss using anti-gdf15 antibodies | |
| CN115944741A (zh) | 含TGF-β受体的融合蛋白与紫杉类、核苷类似物联合在制备治疗胰腺癌药物中的用途 | |
| KR20260053090A (ko) | 항-cd38 항체의 피하 제제 및 이의 용도 | |
| KR20260053410A (ko) | 항-cd38 항체의 피하 제제 및 이의 용도 |